3-oxo-3-(3-(trifluoromethyl)phenyl)propanal | 869961-91-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-oxo-3-(3-(trifluoromethyl)phenyl)propanal
• 英文别名: 3-Oxo-3-[3-(trifluoromethyl)phenyl]propanal
• CAS: 869961-91-1
• 化学式: C₁₀H₇F₃O₂
• 分子量: 216.16
• InChiKey: XSPHLTYDVJZYKE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-oxo-3-(3-(trifluoromethyl)phenyl)propanal 在 盐酸羟胺 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 17.0h， 生成 5-(3-(trifluoromethyl)phenyl)isoxazole
  参考文献：
  名称：

  Identification and optimisation of 5-amino-7-aryldihydro-1,4-diazepines as 5-HT2A ligands

  摘要：

  A several series of low molecular weight 5-HT2A leads were identified from an analysis of HTS data, the exploration of SAR and optimization of one series using parallel synthesis are described, affording compound 22 (5-HT2A IC50 1.1 nM). (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.08.108
• 作为产物：
  描述：

  间三氟甲基苯乙酮 、 甲酸乙酯 在 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 反应 2.5h， 生成 3-oxo-3-(3-(trifluoromethyl)phenyl)propanal
  参考文献：
  名称：

  Identification and optimisation of 5-amino-7-aryldihydro-1,4-diazepines as 5-HT2A ligands

  摘要：

  A several series of low molecular weight 5-HT2A leads were identified from an analysis of HTS data, the exploration of SAR and optimization of one series using parallel synthesis are described, affording compound 22 (5-HT2A IC50 1.1 nM). (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.08.108

文献信息

• Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
  申请人：Griffin John

  公开号：US20050261354A1

  公开（公告）日：2005-11-24

  The present invention provides compositions of matter, kits and methods for their use in the treatment of MAP kinase-related conditions and/or HMG-CoA reductase-related conditions. In particular, the invention provides compositions for treating inflammatory and/or cardiovascular conditions in an animal subject by inhibiting p38α MAP kinase and/or HMG-CoA reductase, as well as providing formulations and modes of administering such compositions. The invention further provides methods for the rational design of inhibitors of MAP kinase, HMG-CoA reductase, or both for use in the practice of the present invention.

  本发明提供了物质组合物、试剂盒和它们在治疗MAP激酶相关疾病和/或HMG-CoA还原酶相关疾病中的应用的方法。具体而言，本发明提供了用于通过抑制p38α MAP激酶和/或HMG-CoA还原酶来治疗动物主体的炎症和/或心血管疾病的组合物，以及提供这些组合物的配方和给药方式。本发明还提供了用于有理设计MAP激酶、HMG-CoA还原酶或两者的抑制剂的方法，用于实施本发明。
• COMPOSITIONS AND TREATMENTS FOR INHIBITING KINASE AND/OR HMG-COA REDUCTASE
  申请人：Griffin John

  公开号：US20070004758A1

  公开（公告）日：2007-01-04

  The present invention provides compositions of matter, kits and methods for their use in the treatment of MAP kinase-related conditions and/or HMG-CoA reductase-related conditions. In particular, the invention provides compositions for treating inflammatory and/or cardiovascular conditions in an animal subject by inhibiting p38α MAP kinase and/or HMG-CoA reductase, as well as providing formulations and modes of administering such compositions. The invention further provides methods for the rational design of inhibitors of MAP kinase, HMG-CoA reductase, or both for use in the practice of the present invention.

  本发明提供了物质组成物、试剂盒和它们的使用方法，用于治疗与MAP激酶相关的疾病和/或HMG-CoA还原酶相关的疾病。特别地，本发明提供了用于通过抑制p38α MAP激酶和/或HMG-CoA还原酶治疗动物主体的炎症和/或心血管疾病的组成物，并提供了这种组成物的配方和给药方式。本发明还提供了用于有理设计MAP激酶、HMG-CoA还原酶或两者抑制剂的方法，以在本发明的实践中使用。
• US7183285B2
  申请人：——

  公开号：US7183285B2

  公开（公告）日：2007-02-27
• US7199126B2
  申请人：——

  公开号：US7199126B2

  公开（公告）日：2007-04-03
• US7163945B2
  申请人：——

  公开号：US7163945B2

  公开（公告）日：2007-01-16